China’s HUYA Biotech, Solvay Of U.S. To Partner In Drug Development
This article was originally published in PharmAsia News
Executive Summary
China's HUYA Bioscience International has signed a deal with U.S.-based Solvay Pharmaceuticals to share HUYA's portfolio of compounds. HUYA has several compounds for targeting cardiovascular diseases and a partnership with Solvay is seen as one way to speed development and get the drugs to market. Many of the compounds already are in advanced stages of development in China. The Chinese biotech counts two headquarters, one in Shanghai and the other in San Diego. (Click here for more
You may also be interested in...
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.